# Teriparatide

Canonical source: https://retacompare.com/encyclopedia/teriparatide

Intermittent PTH receptor activation paradoxically stimulates osteoblastic bone formation more than osteoclastic resorption.

Reference facts

Also known asForteo, PTH 1-34, rhPTH(1-34)CategoryBone & CalciumMechanism of actionIntermittent PTH receptor activation paradoxically stimulates osteoblastic bone formation more than osteoclastic resorption.TargetsPTH1RIndications under research or approvedSevere osteoporosis (post-menopausal women, men, glucocorticoid-induced)Regulatory status (reference entry)FDA-approved (2002)Half-life~1 hourSequenceSVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFSequence notes34-residue N-terminal active fragment of human parathyroid hormone, recombinant.Molecular weight (Da)4118PDB accession1ET1Originator / sponsorEli LillyFirst reported1995
    Primary References

Neer et al., NEJM 2001 (Forteo pivotal)


    Explore research articles about Teriparatide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Neer et al., NEJM 2001 (Forteo pivotal): https://www.nejm.org/doi/full/10.1056/NEJM200105103441904